Diverse subsets of endothelial progenitor cells (EPCs) are used for the treatment of ischemic
diseases in clinical trials, and circulating EPCs levels are considered as biomarkers for …

Type 2 diabetes is characterized by a two-to fourfold increased risk of cardiovascular
disease. This is generally attributed to the adverse effects of hyperglycemia and oxidative …

Human endothelial progenitor cells (EPCs) have been generally defined as circulating cells
that express a variety of cell surface markers similar to those expressed by vascular …

BACKGROUND: Peripheral arterial disease (PAD) is a common cause of disability and
mortality. Up to one third of patients are not susceptible to traditional revascularization and …

OBJECTIVE Diabetes mellitus (DM) increases cardiovascular risk, at least in part, through
shortage of vascular regenerative cells derived from the bone marrow (BM). In experimental …

In the last 10 years an increasing interest has been devoted to the study of endothelial
progenitor cells (EPCs), a subtype of immature cells involved in endothelial repair and …

The cardiovascular and haematopoietic systems have fundamental inter-relationships
during development, as well as in health and disease of the adult organism. Although …

The recognition of a central role for the endothelium in the development of kidney disease or
the development of vascular lesions in patients with established renal dysfunction has led to …

OBJECTIVE Reduction of bone marrow–derived circulating progenitor cells has been
proposed as a novel mechanism of cardiovascular disease in type 2 diabetes. The present …

Atherosclerotic diseases are responsible for a significant part of morbidity and mortality in
western countries. According to the classical views, atherosclerotic lesions develop as the …